AU2021396659A1 - Modulating th1/th2 immune response by administering two populations of polymersomes having an associated antigen and an associated adjuvant - Google Patents

Modulating th1/th2 immune response by administering two populations of polymersomes having an associated antigen and an associated adjuvant Download PDF

Info

Publication number
AU2021396659A1
AU2021396659A1 AU2021396659A AU2021396659A AU2021396659A1 AU 2021396659 A1 AU2021396659 A1 AU 2021396659A1 AU 2021396659 A AU2021396659 A AU 2021396659A AU 2021396659 A AU2021396659 A AU 2021396659A AU 2021396659 A1 AU2021396659 A1 AU 2021396659A1
Authority
AU
Australia
Prior art keywords
seq
polymersomes
poly
antigen
cov
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021396659A
Other languages
English (en)
Other versions
AU2021396659A9 (en
Inventor
Thomas Andrew CORNELL
Fabien DECAILLOT
Amit Kumar KHAN
Jian Hang LAM
Madhavan Nallani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ACM Biolabs Pte Ltd
Original Assignee
ACM Biolabs Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ACM Biolabs Pte Ltd filed Critical ACM Biolabs Pte Ltd
Publication of AU2021396659A1 publication Critical patent/AU2021396659A1/en
Publication of AU2021396659A9 publication Critical patent/AU2021396659A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2021396659A 2020-12-11 2021-12-13 Modulating th1/th2 immune response by administering two populations of polymersomes having an associated antigen and an associated adjuvant Pending AU2021396659A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20213488.8 2020-12-11
EP20213488 2020-12-11
PCT/EP2021/085366 WO2022123070A1 (en) 2020-12-11 2021-12-13 Modulating th1/th2 immune response by administering two populations of polymersomes having an associated antigen and an associated adjuvant

Publications (2)

Publication Number Publication Date
AU2021396659A1 true AU2021396659A1 (en) 2023-05-04
AU2021396659A9 AU2021396659A9 (en) 2023-07-13

Family

ID=74187071

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021396659A Pending AU2021396659A1 (en) 2020-12-11 2021-12-13 Modulating th1/th2 immune response by administering two populations of polymersomes having an associated antigen and an associated adjuvant

Country Status (6)

Country Link
US (1) US20230398207A1 (https=)
EP (1) EP4259197A1 (https=)
JP (1) JP2024500360A (https=)
AU (1) AU2021396659A1 (https=)
CA (1) CA3193643A1 (https=)
WO (1) WO2022123070A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201704135QA (en) * 2012-11-19 2017-06-29 Agency Science Tech & Res Method For Eliciting An Immune Response To An Immunogen
EP4604997A2 (en) * 2022-10-21 2025-08-27 PDS Biotechnology Corporation Recombinant protein vaccines formulated with enantio-specific cationic lipid r-dotap and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
EP2281033B1 (en) 2008-04-17 2014-10-15 Vin de Bona Trading Co Pte Post release modification of viral envelopes
US8323696B2 (en) 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy
CN102460150B (zh) 2009-04-20 2015-05-20 新加坡科技研究局 囊泡系统及其用途
EP2601262A4 (en) 2010-08-05 2014-01-22 Agency Science Tech & Res VESIGN STRUCTURE WITH SEVERAL CHAMBERS AND METHOD FOR THEIR EDUCATION
CA2866170A1 (en) 2012-03-12 2013-09-19 Advanced Bioadjuvants, Llc Adjuvant and vaccine compositions
DK2906717T3 (en) 2012-10-11 2019-04-01 Vin De Bona Trading Company Pte Ltd PROCEDURE FOR PAINTING MICROVESICS
SG10201704135QA (en) 2012-11-19 2017-06-29 Agency Science Tech & Res Method For Eliciting An Immune Response To An Immunogen
KR101943171B1 (ko) * 2013-09-19 2019-01-29 조에티스 서비시즈 엘엘씨 유성 아쥬반트
EP2898894A1 (en) 2014-01-27 2015-07-29 LTS LOHMANN Therapie-Systeme AG Nano-in-micro particles for intradermal delivery
US9636397B2 (en) 2015-03-24 2017-05-02 VaxLiant, LLC Adjuvant compositions and related methods
US10696985B1 (en) * 2016-06-06 2020-06-30 Vanderbilt University Reversibly crosslinked endosomolytic polymer vesicles for cytosolic drug delivery
EP3743101A2 (en) * 2018-01-25 2020-12-02 ACM Biolabs Pte Ltd Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof
CN114502191B (zh) * 2019-08-01 2026-04-03 Acm生物实验室私人有限公司 通过施用具有关联的抗原的聚合物囊泡群和具有关联的佐剂的聚合物囊泡群来引发免疫应答的方法以及包含这两种聚合物囊泡群的组合物
US20230256082A1 (en) * 2020-04-24 2023-08-17 Acm Biolabs Pte Ltd Vaccine against human-pathogenic coronaviruses

Also Published As

Publication number Publication date
EP4259197A1 (en) 2023-10-18
JP2024500360A (ja) 2024-01-09
AU2021396659A9 (en) 2023-07-13
US20230398207A1 (en) 2023-12-14
CA3193643A1 (en) 2022-06-16
WO2022123070A1 (en) 2022-06-16

Similar Documents

Publication Publication Date Title
US20220273792A1 (en) A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersomes
US20250186346A1 (en) Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof
CN103747797B (zh) 脂质体制剂
US20230398207A1 (en) Modulating th1/th2 immune response by administering two populations of polymersomes having an associated antigen and an associated adjuvant
US20230256082A1 (en) Vaccine against human-pathogenic coronaviruses
US20250281405A1 (en) Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
EP3849600A1 (en) Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
EP4288033B1 (en) Polymersome associated adjuvant for use in stimulating an immune response
WO2015153883A1 (en) Vaccination using plant virus particles linked to her2 antigens

Legal Events

Date Code Title Description
SREP Specification republished